Literature DB >> 3917426

Cytotoxicity of human serum for Leishmania donovani amastigotes: antibody facilitation of alternate complement pathway-mediated killing.

D L Hoover, M Berger, M H Oppenheim, W T Hockmeyer, M S Meltzer.   

Abstract

Mechanisms that mediate recovery from leishmanial infection have not been fully characterized but are generally believed to involve interactions between T lymphocytes and macrophages. A major role for serum-mediated effector mechanisms in the protection of humans from reinfection with Leishmania, however, has not been ruled out. In this report, amastigotes of L. donovani were incubated with dilutions of serum from normal subjects and from patients with kala-azar. Normal serum was cytotoxic for parasites at a dilution of greater than or equal to 1:20. Cytotoxicity did not occur in the presence of EDTA, was abolished by heating serum to 56 degrees C for 30 min, and was not diminished by prior adsorption of normal serum with parasites at 0 degree C. Killing proceeded normally in the presence of magnesium-ethylene glycol-bis(beta-aminoethyl ether)-N, N-tetraacetic acid, however, and was fully effected by C2-deficient serum. These studies indicated that killing of amastigotes, unlike that of promastigotes, was mediated via the alternate pathway of serum complement. In further studies, cytotoxicity of normal serum was enhanced three- to fivefold by factors in patient serum. This enhanced cytotoxicity also proceeded via the alternate complement pathway. Factors that enhanced cytotoxicity were characterized as parasite-specific immunoglobulin G: they eluted with immunoglobulin G on column chromatography, were adsorbed by immobilized staphylococcal protein A, and were not removed from the parasite surface by extensive washing. Thus, infection of individuals with L. donovani resulted in the production of a new, qualitatively and quantitatively distinct immune mechanism directed against the amastigote form of the parasite, namely, antibody-directed, alternate complement pathway-mediated cytotoxicity. These results provide a mechanistic framework for a role of humoral factors in human resistance to reinfection with L. donovani.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917426      PMCID: PMC261503          DOI: 10.1128/iai.47.1.247-252.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  12 in total

Review 1.  Current status of the immunology of blood and tissue Protozoa. I. Leishmania.

Authors:  A Zuckerman
Journal:  Exp Parasitol       Date:  1975-12       Impact factor: 2.011

2.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

3.  New culture medium for maintenance of tsetse tissues and growth of trypanosomatids.

Authors:  I Cunningham
Journal:  J Protozool       Date:  1977-05

4.  Prevention of varicella in high risk children: a collaborative study.

Authors:  P A Brunell; A A Gershon; W T Hughes; H D Riley; J Smith
Journal:  Pediatrics       Date:  1972-11       Impact factor: 7.124

5.  Analysis of macrophage interactions with cryopreserved amastigotes of Leishmania tropica.

Authors:  D L Hoover; C A Nacy
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

6.  Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse.

Authors:  P M Preston; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

7.  Antibody-induced modulation of Leishmania donovani surface membrane antigens.

Authors:  D M Dwyer
Journal:  J Immunol       Date:  1976-12       Impact factor: 5.422

8.  Intracellular replication and lymphokine-induced destruction of Leishmania tropica in C3H/HeN mouse macrophages.

Authors:  C A Nacy; M S Meltzer; E J Leonard; D J Wyler
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

9.  Immunological responses of L. donovani infection in mice and significance of T cell in resistance to experimental leishmaniasis.

Authors:  H R Rezai; J Farrell; E L Soulsby
Journal:  Clin Exp Immunol       Date:  1980-06       Impact factor: 4.330

10.  Mechanism of lethal effect of human serum upon Leishmania donovani.

Authors:  R D Pearson; R T Steigbigel
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

View more
  5 in total

1.  Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies.

Authors:  Ricardo Silvestre; Anabela Cordeiro-da-Silva; Joana Tavares; Denis Sereno; Ali Ouaissi
Journal:  Immunology       Date:  2006-10-09       Impact factor: 7.397

2.  The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients.

Authors:  A M Elassad; S A Younis; M Siddig; J Grayson; E Petersen; H W Ghalib
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

3.  Bispecific mAb2 Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab.

Authors:  Katharina Stadlbauer; Peter Andorfer; Gerhard Stadlmayr; Florian Rüker; Gordana Wozniak-Knopp
Journal:  Int J Mol Sci       Date:  2022-05-06       Impact factor: 6.208

4.  Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway.

Authors:  M X Zhang; T R Kozel
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

5.  Different host complement systems and their interactions with saliva from Lutzomyia longipalpis (Diptera, Psychodidae) and Leishmania infantum promastigotes.

Authors:  Antonio Ferreira Mendes-Sousa; Alexandre Alves Sousa Nascimento; Daniel Costa Queiroz; Vladimir Fazito Vale; Ricardo Toshio Fujiwara; Ricardo Nascimento Araújo; Marcos Horácio Pereira; Nelder Figueiredo Gontijo
Journal:  PLoS One       Date:  2013-11-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.